Show simple item record

AuthorAlalawneh, Majdoleen
AuthorRachid, Ousama
AuthorAbdallah, Ibtihal
AuthorMahfouz, Ahmed
AuthorElewa, Hazem
AuthorDanjuma, Mohammed Ibn-Mas'ud
AuthorMohamed, Asmaa Ezzeldin
AuthorAwaisu, Ahmed
Available date2023-12-28T05:14:42Z
Publication Date2023
Publication NameEuropean Journal of Clinical Pharmacology
ResourceScopus
ISSN316970
URIhttp://dx.doi.org/10.1007/s00228-023-03572-7
URIhttp://hdl.handle.net/10576/50637
AbstractPurpose To investigate real-world prescribing trends and clinical outcomes based on body mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This was a retrospective cohort study involving all patients who received rivaroxaban therapy across all Hamad Medical Corporation (HMC) hospitals from 2015 to 2020. Results The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3%) in 2015 to 1342 (28.9%) in 2020 (p <0.001). Within BMI categories, a similar increasing trend was observed in underweight, normal, and overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban prescribing in all obese classes. The prevalence rate of all-cause mortality differed significantly between the BMI groups, with the highest mortality being among morbidly obese patients (BMI ≥ 40 kg/m2) (p< 0.001). On the other hand, no significant differences were found between the BMI groups in terms of bleeding, pulmonary embolism, deep vein thrombosis and stroke incidences. Multivariate logistic regression analyses showed that the likelihood of all-cause mortality was significantly higher in overweight and all categories of obese patients compared to underweight patients: overweight (OR: 5.3, 95% CI: 2.3–11.9, p< 0.001); obese class 1 (OR: 5.4, 95% CI: 2.3 – 12.2, p< 0.001); obese class 2 (OR: 6.5, 95% CI: 2.7 – 15.6, p< 0.001); and obese class 3 (OR: 3.7, 95% CI: 1.6 – 8.7, p = 0.003). Conclusions Rivaroxaban prescribing has significantly increased over the years across general population, with a noticeable decline in obese population during the last few years (from 2018 onwards). Furthermore, an appreciable association was evident between all-cause mortality and BMI of these patients.
SponsorThe study protocol and other associated study documents were approved by the HMC's Medical Research Centre (MRC-01-22-102) and the Institutional Review Board (IRB) at Qatar University before study initiation (QU-IRB1743-E/22).
Languageen
PublisherSpringer Science and Business Media Deutschland GmbH
SubjectBody mass index
Clinical outcomes
Direct oral anticoagulants
Obese
Rivaroxaban
Acute scrotum
Testicular torsion
Torsion of the appendix testis
Children
TitleTrends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
TypeArticle
Pagination1675-1685
Issue Number12
Volume Number79
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record